Angiex Private Investor Briefing – Virtual

Event Details

Angiex Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

TUESDAY, February 3, 2026

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Opus8 is hosting a small, invitation-only private investor briefing featuring Angiex, a clinical-stage oncology company advancing a first-in-class platform of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) for solid tumors.

This closed-door session will provide direct access to Angiex’s leadership team and an opportunity to review the company’s lead Phase 1 clinical program, emerging clinical signals, platform differentiation, and upcoming milestones, as well as a discussion of current financing opportunities for accredited investors.

Angiex is entering a critical value-creation phase, with early clinical data beginning to inform downstream strategic and capital formation decisions.

Company Overview

Angiex is developing a new class of antibody-drug conjugates designed to deliver therapeutic payloads directly to the nucleus of tumor cells and tumor-associated vasculature. The company’s lead asset, AGX101, targets TM4SF1, a protein highly expressed in tumor blood vessels and tumor cells, with limited expression in normal adult tissues.

AGX101 is currently in Phase 1 clinical trials in patients with advanced solid tumors and has demonstrated an exceptional safety profile alongside early signs of clinical activity, including stable disease and tumor shrinkage at higher dose levels.

What Differentiates Angiex

First-in-Class Nuclear-Delivered ADC Platform — Designed to bypass traditional ADC resistance mechanisms through direct nuclear payload delivery
Validated Tumor Target (TM4SF1) — Enables dual targeting of tumor vasculature and tumor cells
Three Complementary Mechanisms of Action — Vascular deprivation, immune activation, and direct tumor cell killing
Outstanding Safety Profile — No observed adverse effects in primate studies at the highest dose tested
Early Clinical Validation — On-target pharmacodynamics and emerging tumor response in Phase 1

Event Details

Date: Tuesday, February 3, 2026
Time: 11:30 – 12:30 PM EST
Location: Online via Zoom

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials, contact:
Skylar Rallison — srallison@opus8.com

Event Details